Richmond Pharmacology receives MHRA Standard and Supplementary Accreditation for 2 hospital bases

06 Mar 2009


Richmond Pharmacology receives MHRA Standard and Supplementary Accreditation for 2 hospital bases

Richmond Pharmacology Ltd. (RPL) have proudly received MHRA Standard and Supplementary Accreditation, a clear sign of our continued commitment to providing the highest level of subject safety on all studies conducted within our two hospital based Early Phase trial centres. RPL is unique in being the only Early Phase CRO in the UK to have two trial centres based in two acute NHS teaching hospitals.

The supplementary accreditation confirms that RPL have attained the highest level of accreditation available in Europe. This permits RPL to perform the full range of Early Phase studies, including trials requiring a review of risk factors by the Expert Advisory Group (EAG).

The combination of this accreditation award, our experience from conducting in excess of 400 Early Phase studies and our world-leading scientific advisory board means our sponsors can rely on RPL to continue to lead the industry in the conduct of FTIM studies, as well as other specialty areas such as QTc studies, Japanese bridging studies, gastrointestinal studies and patient studies.

For more information on the MHRA Phase I accreditation scheme visit the MHRA website

« back to news and events

Case studies

The thorough approach to QTc studies ("Your perfect partner for conducting definitive thorough QT studies, all under one roof")

Timelines, Tight Timelines and Even Tighter Timelines in a Phase I Environment (We know we can help your business. We always rise to the challenge)